399 related articles for article (PubMed ID: 26176936)
21. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.
Woodruff PG; Agusti A; Roche N; Singh D; Martinez FJ
Lancet; 2015 May; 385(9979):1789-1798. PubMed ID: 25943943
[TBL] [Abstract][Full Text] [Related]
22. Surfactant protein D as a biomarker for chronic obstructive pulmonary disease.
Bowler RP
COPD; 2012 Dec; 9(6):651-3. PubMed ID: 23244171
[TBL] [Abstract][Full Text] [Related]
23. Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium.
Miller BE; Tal-Singer R; Rennard SI; Furtwaengler A; Leidy N; Lowings M; Martin UJ; Martin TR; Merrill DD; Snyder J; Walsh J; Mannino DM
Am J Respir Crit Care Med; 2016 Mar; 193(6):607-13. PubMed ID: 26745765
[TBL] [Abstract][Full Text] [Related]
24. Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious?
Soler-Cataluña JJ; Rodriguez-Roisin R
COPD; 2010 Aug; 7(4):276-84. PubMed ID: 20673037
[TBL] [Abstract][Full Text] [Related]
25. Predictors of chronic obstructive pulmonary disease exacerbations.
Ishii T; Kida K
Curr Opin Pulm Med; 2014 Mar; 20(2):138-45. PubMed ID: 24406871
[TBL] [Abstract][Full Text] [Related]
26. Personalized management of chronic obstructive pulmonary disease via transcriptomic profiling of the airway and lung.
Steiling K; Lenburg ME; Spira A
Ann Am Thorac Soc; 2013 Dec; 10 Suppl(Suppl):S190-6. PubMed ID: 24313772
[TBL] [Abstract][Full Text] [Related]
27. Search for biomarkers in chronic obstructive pulmonary disease: current status.
Nicholas BL
Curr Opin Pulm Med; 2013 Mar; 19(2):103-8. PubMed ID: 23361193
[TBL] [Abstract][Full Text] [Related]
28. Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma.
Fujii K; Nakamura H; Nishimura T
Expert Rev Proteomics; 2017 Apr; 14(4):373-386. PubMed ID: 28271730
[TBL] [Abstract][Full Text] [Related]
29. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits.
Mathioudakis AG; Janssens W; Sivapalan P; Singanayagam A; Dransfield MT; Jensen JS; Vestbo J
Thorax; 2020 Jun; 75(6):520-527. PubMed ID: 32217784
[TBL] [Abstract][Full Text] [Related]
30. Proteomics-based biomarkers in chronic obstructive pulmonary disease.
Chen H; Wang D; Bai C; Wang X
J Proteome Res; 2010 Jun; 9(6):2798-808. PubMed ID: 20387909
[TBL] [Abstract][Full Text] [Related]
31. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic mechanisms in COPD: implications for pathogenesis and drug discovery.
Schamberger AC; Mise N; Meiners S; Eickelberg O
Expert Opin Drug Discov; 2014 Jun; 9(6):609-28. PubMed ID: 24850530
[TBL] [Abstract][Full Text] [Related]
33. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations.
Farland MZ; Peters CJ; Williams JD; Bielak KM; Heidel RE; Ray SM
Ann Pharmacother; 2013 May; 47(5):651-6. PubMed ID: 23585645
[TBL] [Abstract][Full Text] [Related]
34. The future of chronic obstructive pulmonary disease treatment--difficulties of and barriers to drug development.
Martinez FJ; Donohue JF; Rennard SI
Lancet; 2011 Sep; 378(9795):1027-37. PubMed ID: 21907866
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations - Part 1.
Russo P; Lococo F; Kisialiou A; Prinzi G; Lamonaca P; Cardaci V; Tomino C; Fini M
Curr Med Chem; 2019; 26(10):1721-1733. PubMed ID: 29852859
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Biomarkers Based on Proteomic Technology in COPD: A Recent Review.
Fang H; Liu Y; Yang Q; Han S; Zhang H
Int J Chron Obstruct Pulmon Dis; 2023; 18():1353-1365. PubMed ID: 37408604
[TBL] [Abstract][Full Text] [Related]
37. Proteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entities.
O'Neil SE; Lundbäck B; Lötvall J
J Proteomics; 2011 Dec; 75(1):192-201. PubMed ID: 22037230
[TBL] [Abstract][Full Text] [Related]
38. [Impact of exacerbations on the clinical course of chronic obstructive pulmonary disease].
Soler-Cataluña JJ; Martínez-García MA; Catalán Serra P; Román Sánchez P
Rev Clin Esp; 2011 Mar; 211 Suppl 2():3-12. PubMed ID: 21596168
[TBL] [Abstract][Full Text] [Related]
39. Advances in proteomic techniques for biomarker discovery in COPD.
Casado B; Luisetti M; Iadarola P
Expert Rev Clin Immunol; 2011 Jan; 7(1):111-23. PubMed ID: 21162654
[TBL] [Abstract][Full Text] [Related]
40. Precision Approaches to Chronic Obstructive Pulmonary Disease Management.
Moll M; Silverman EK
Annu Rev Med; 2024 Jan; 75():247-262. PubMed ID: 37827193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
